Covalent PROTACs: the best of both worlds?,RSC Medicinal Chemistry

当前位置： X-MOL 学术 › RSC Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Covalent PROTACs: the best of both worlds?
RSC Medicinal Chemistry ( IF 4.1 ) Pub Date : 2021-07-15 , DOI: 10.1039/d1md00191d
Neil P Grimster ₁

Affiliation

Covalent PROTACs combine the cutting edge research areas of targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs). This nascent field of research has already demonstrated several interesting findings, and holds an immense amount of potential to expand the druggable proteome. In this opinion, we present some of these intriguing early findings and discuss the potential advantages and disadvantages of this approach.

中文翻译：

共价 PROTAC：两全其美？

共价 PROTAC 结合了靶向共价抑制剂 (TCI) 和蛋白水解靶向嵌合体 (PROTAC) 的前沿研究领域。这个新兴的研究领域已经展示了一些有趣的发现，并且具有扩展可药物蛋白质组的巨大潜力。在这个观点中，我们提出了一些有趣的早期发现，并讨论了这种方法的潜在优点和缺点。

更新日期：2021-07-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文